An interventional study of Therapeutic Drug Monitoring for Linezolid in Rifampin-resistant Tuberculosis and Drug-resistant Tuberculosis, sponsored by Albert Einstein College of Medicine. Recruiting at 1 site in South Africa. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Albert Einstein College of Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa — 7 open to participants now, 8 under way, 3 of them phase 3. Tuberculosis, Multidrug-Resistant · South Africa.
Among the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, this one is the 17th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2026, is one of 8 with no phase, and was the 44th registered.
132 studies on the registry are indexed under Tuberculosis, Multidrug-Resistant; 25 are open to participants now.
Browse Tuberculosis, Multidrug-Resistant studies →7 of the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa are open now. Recruiting first, the newest first:
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in South Africa, China, Georgia and 7 more countries
Ages 14+
University of California, San Francisco · Sites in South Africa
Johns Hopkins University · Sites in South Africa
Ages 18+
Columbia University · Sites in South Africa
Ages 18+ · Healthy volunteers
Seoul National University Hospital · Sites in South Africa
Ages 15+
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 16 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 194 across 88 interventional studies indexed under Tuberculosis, Multidrug-Resistant.
Median enrollment 248 across the 37 interventional studies, 786 across the 9 observational. Of the 32 that completed or were terminated, 17 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 46 have an industry lead sponsor. The 10 most frequent:
Albert Einstein College of Medicine is the lead sponsor of 201 studies on the registry; 21 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 37 (80%) have results posted.
Albert Einstein College of Medicine has 1 study filed under Tuberculosis, Multidrug-Resistant — fewer than ten, so there is no comparison to draw.
2 of the studies in Tuberculosis, Multidrug-Resistant with a site in South Africa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05553236University of California, San FranciscoPragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis | 2027-01 |
| NCT05633056Columbia UniversityAn Adaptive Randomized Controlled Trial | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a two-arm, pragmatic, open-label, randomized clinical trial to determine the efficacy of Therapeutic Drug Monitoring (TDM) in preventing premature discontinuation of Linezolid (LZD) in participants with Rifampicin-resistant tuberculosis (RR-TB). Following the initiation of treatment, participants will be monitored throughout the approximate 6-month duration of RR-TB therapy.
Drug-resistant tuberculosis (TB) is a major global epidemic and poses a particular threat to HIV-infected individuals. With limited effective drugs available for treatment, multidrug-, and extensively drug-resistant TB carry a high mortality rate and threaten global TB and HIV control efforts.
New and repurposed medications have recently been found to improve survival and cure rates. Linezolid-a drug initially developed for the treatment of Gram-positive infections-has considerable anti-TB activity and has been at the center of this treatment revolution. Since 2018, WHO has recommended that all multi DR/rifampicin-resistant (MDR) and extensively drug-resistant tuberculosis (XDR) tuberculosis treatment regimens include linezolid. When given long-term, however, linezolid-associated toxicity-particularly myelosuppression and peripheral neuropathy-is very common, affecting 50-80% of patients and often requiring a temporary or permanent discontinuation of therapy. Such interruptions put patients at risk of treatment failure and the emergence of additional resistance to linezolid or one of the other drugs in the regimen. As linezolid use continues to increase worldwide, such resistance could become widespread, squandering a valuable medication. Previously conducted research has shown that linezolid toxicities are associated with trough plasma concentration and that the drug has considerable inter-individual variability. The investigator team, therefore, hypothesize that therapeutic drug monitoring (TDM) could identify those with higher linezolid concentrations and permit pre-emptive dose reductions that could avert drug toxicity and premature discontinuation.
This study will take place at the Nkqubela TB Specialist Hospital in East London, South Africa. TB diagnosis and initial treatment regimen will be determined by the hospital clinical team, per local guidelines. Following enrollment, participants will be randomized after enrollment to either undergo a therapeutic drug monitoring (TDM) strategy for LZD, or standard of care (SOC). Participants in both arms will have a trough plasma linezolid concentration drawn approximately one week after enrollment (within one month of TB treatment initiation). The PK specimens collected from TDM arm participants will be analyzed by University of Cape Town lab staff. The PK specimens collected from SOC participants will be stored for future analysis.
Standard treatment for RR-TB in South Africa includes 6 months of therapy, including linezolid 600 mg daily for duration of treatment. Those in the TDM arm whose concentration is above a set threshold (2.5 mg/L) will have their LZD dose reduced to 300mg daily, while those in the SOC arm will receive routine monitoring alone. All participants will be screened monthly for hematologic and neurologic toxicity. Hospital and clinic providers will manage all treatment other than the TDM-guided linezolid dose reduction. If participants in either the SOC or TDM arm experience linezolid toxicity, hospital and clinic providers may choose to temporarily or permanently discontinue linezolid, regardless of any prior TDM-guided dose reduction, in accordance with South African national guidelines.
Aim 1 (Primary Outcome Measure of this study) and Aim 2 (the first Secondary Outcome Measure) are described in the Outcome Measures section. For Aim 3, population PK modeling will be used to explore the complex relationship between linezolid pharmacokinetic parameters and the trajectory of toxicities over time. It will also be determined as to whether those whose dose is lowered still meet exposure targets for drug efficacy. South Africa has among the highest global burden of drug-resistant TB and HIV and has led the world in the rollout of new RR-TB drugs and regimens. The aims of this study will answer fundamental questions about LZD pharmacology that will directly inform its use in South Africa and worldwide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
status is known and confirmed
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the TDM arm will have their linezolid dose reduced if their trough concentration is greater than 2.5 mg/L
Other: Therapeutic Drug Monitoring for Linezolid
Participants in the SOC arm will have their linezolid adjusted or held if they develop clinical adverse events.
TDM with dose adjustment for trough concentration \>2.5 mg/L LZD
Discontinuation of Linezolid or non-TDM guided dose reduction
Linezolid (LZD) discontinuation for any cause along with non-TDM-guided LZD dose reduction will be assessed. The number of participants who discontinue LZD (defined as an interruption \> 2 weeks in duration), including self-discontinuation by the patient or a decision by the provider to temporarily or permanently discontinue LZD, OR have a non-TDM-guided dose-reduction in response to an adverse event, will be summarized by study arm using basic descriptive statistics.
Time frame: Within 6 months after initiation of LZD therapy
Evidence of Linezolid Toxicity
Evidence of Linezolid (LZD) toxicity will be evaluated by the number of participants who experience Grade 3 or Grade 4 hematologic (e.g., anemia, thrombocytopenia, neutropenia) or neurologic (e.g., peripheral neuropathy or optic neuritis) adverse events associated with LZD toxicity. LZD-associated Grade 3 or Grade 4 events, documented at any time point up to 6 months, will be summarized by adverse event type and frequency for each study arm.
Time frame: Within 6 months after initiation of LZD therapy
Unsuccessful final Tuberculosis (TB) end-of-treatment outcome
Unsuccessful final TB treatment outcome is defined as either treatment failure, death, or participant lost to follow-up, as per World Health Organization (WHO) definitions, defined below. End-of-treatment TB outcomes will be captured for all study participants. The number of participants with unsuccessful final TB treatment outcomes will be summarized by study arm using basic descriptive statistics. TB treatment outcomes will be assessed at the end of 6 months of treatment; however, if treatment is extended for any reason, medical records will be reviewed 12 months after treatment initiation to capture a final TB treatment outcome. Treatment failure: The patient's treatment was terminated or they needed to permanently change their regimen due to a lack of response to treatment, adverse drug reaction, or increased drug resistance. Lost to follow-up: The patient stopped taking their medication for two or more months in a row after registering. Death: The patient died
Time frame: After 6 months, and up to 12 months after initiation of LZD therapy
Emergence of new phenotypic resistance to Linezolid
The percentage of participants in each arm who develop phenotypic Linezolid (LZD) resistance will be assessed. Participants who experience treatment failure and remain sputum culture-positive after 4 months, will have a sputum sample collected for additional drug-resistance testing. Results of any isolates which undergo such resistance testing will be reviewed to identify anyone with treatment-emergent linezolid resistance. Additionally, during follow-up visits, participants will be directly assessed for development of LZD resistance. The percentage of participants who develop phenotypic resistance to LZD, as determined by either of these methods, will be summarized by study arm using basic descriptive statistics
Time frame: Within 6 months after initiation of LZD therapy
TB-free survival
TB-free survival will be assessed by review of each participant's medical record as well as EDRWeb, a South African registry of patients with drug-resistant tuberculosis, to determine whether or not the participant is still alive and free of TB disease. The number/percentage of participants who are alive and free of TB disease will be summarized by study arm.
Time frame: 12 months after initiation of LZD therapy
Non-TDM-guided dose reduction of linezolid
At each study visit, the participant's medical and pharmacy records will be reviewed to determine if the hospital or clinical provider has decreased the dose of linezolid for any reason other than study-related therapeutic drug-monitoring. The number/percentage of participants who had dosage of linezolid decreased will be summarized by study arm.
Time frame: Within 6 months after initiation of LZD therapy
Plan to share: Yes — The study will generate a range of data types from structured participant interviews to linezolid trough plasma concentrations. The investigators aim to widely share the knowledge generated by this proposal to advance knowledge in the field of TB research and avoid duplication of relevant work. Participant-level clinical and laboratory data will be preserved through deposition of the data in a controlled access public repository.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Scientific data included in published manuscripts will be available at the time of publication or the end of the award, whichever comes first; all other generated scientific data will be shared no later than the end of the award. Data will be made available for an indefinite period or until Emory University requests that it be withdrawn.
Access criteria: All de-identified study data not designated as restricted use will be made available to the research community upon request and approval by study MPIs. Code used to perform statistical analysis will be deposited in a publicly available repository or may be requested from the investigators to ensure others can seek to reproduce the results, if desired. Public use and restricted access study data and associated documentation will be made available to the research community free of charge through the Emory Dataverse, an open data repository intended for the preservation, discoverability and accessibility of data produced by the Emory University research community, or other appropriate data repository.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2029, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tuberculosis, Multidrug-Resistant →
Albert Einstein College of Medicine →